Factory Mutual Insurance Co. Makes New Investment in Repligen Corporation $RGEN

Repligen logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Factory Mutual Insurance acquired 9,167 Repligen shares in the third quarter, valued at approximately $1.76 million. Institutional investors collectively own 97.64% of the company’s stock.
  • Repligen reported quarterly EPS of $0.53, topping the $0.46 consensus estimate, while revenue rose 10.9% year over year to $209.31 million.
  • Analyst sentiment is mostly positive: the stock has a “Moderate Buy” consensus rating and an average price target of $178.57, though Weiss Ratings downgraded it to “Sell.”
  • Five stocks to consider instead of Repligen.

Factory Mutual Insurance Co. acquired a new stake in Repligen Corporation (NASDAQ:RGEN - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 9,167 shares of the biotechnology company's stock, valued at approximately $1,762,000.

A number of other institutional investors have also recently bought and sold shares of RGEN. ABS Investment Management LLC acquired a new position in Repligen in the second quarter valued at about $191,016,000. CoreCap Advisors LLC grew its stake in Repligen by 1,275.0% during the third quarter. CoreCap Advisors LLC now owns 275 shares of the biotechnology company's stock worth $53,000 after buying an additional 255 shares in the last quarter. Farther Finance Advisors LLC grew its stake in Repligen by 35.5% during the third quarter. Farther Finance Advisors LLC now owns 374 shares of the biotechnology company's stock worth $72,000 after buying an additional 98 shares in the last quarter. Northwestern Mutual Wealth Management Co. bought a new position in Repligen in the 2nd quarter valued at about $52,000. Finally, Trust Co. of Vermont bought a new position in Repligen in the 2nd quarter valued at about $71,000. Institutional investors own 97.64% of the company's stock.

Repligen Stock Performance

Shares of RGEN stock opened at $178.20 on Thursday. The business's 50-day moving average price is $177.75 and its 200-day moving average price is $145.42. Repligen Corporation has a 12 month low of $100.99 and a 12 month high of $198.87. The firm has a market capitalization of $11.39 billion, a price-to-earnings ratio of 87.39, a PEG ratio of 3.05 and a beta of 1.11. The company has a current ratio of 9.88, a quick ratio of 8.43 and a debt-to-equity ratio of 0.27.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings data on Tuesday, October 27th. The biotechnology company reported $0.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.07. Repligen had a positive return on equity of 5.49% and a negative net margin of 1.47%. The company had revenue of $209.31 million during the quarter, compared to the consensus estimate of $206.70 million. During the same quarter in the prior year, the firm posted $0.46 earnings per share. The firm's revenue was up 10.9% compared to the same quarter last year. Equities research analysts forecast that Repligen Corporation will post 2.07 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Weiss Ratings cut Repligen from a "hold (c)" rating to a "sell (d+)" rating in a report on Monday. UBS Group restated a "buy" rating on shares of Repligen in a research report on Tuesday, September 29th. JPMorgan Chase & Co. raised their price objective on Repligen from $165.00 to $175.00 and gave the company an "overweight" rating in a research note on Wednesday, July 29th. Barclays lifted their target price on Repligen from $175.00 to $225.00 and gave the company an "overweight" rating in a research report on Wednesday, October 7th. Finally, Royal Bank Of Canada boosted their target price on Repligen from $185.00 to $200.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 28th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $178.57.

Read Our Latest Stock Analysis on RGEN

Repligen Company Profile

(Free Report)

Repligen Corporation NASDAQ: RGEN develops and manufactures bioprocessing technologies used in the production of biological medicines. Its products support key stages of biopharmaceutical manufacturing, including upstream processing, downstream purification, filtration, process monitoring and fluid management.

The company's offerings include chromatography products, filtration systems, single-use technologies, process analytics equipment and critical biological materials such as recombinant proteins.

Featured Stories

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Repligen Right Now?

Before you consider Repligen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.

While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines